Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients

被引:447
作者
Dykewicz, CA [1 ]
机构
[1] CDCP, Natl Ctr Infect Dis, Div AIDS STD & TB Lab Res, Atlanta, GA 30333 USA
关键词
D O I
10.1086/321805
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
This article contains highlights of "Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients: Recommendations of the CDC, the Infectious Diseases Society of America, and the American Society of Blood and Marrow Transplantation," which was published in the Morbidity and Mortality Weekly Report. There are sections on the prevention of bacterial, viral, fungal, protozoal, and helminth infections and on hospital infection control, strategies for safe living following transplantation, immunizations, and hematopoietic stem cell safety. The guidelines are evidence-based, and prevention strategies are rated by both the strength of the recommendation and the quality of evidence that supports it. Recommendations are given for preventing cytomegalovirus disease with prophylactic or preemptive gancyclovir, herpes simplex virus disease with prophylactic acyclovir, candidiasis with fluconazole, and Pneumocystis carinii pneumonia with trimethoprim-sulfamethoxazole. Hopefully, following the recommendations made in the guidelines will reduce morbidity and mortality from opportunistic infections in hematopoietic stem cell transplant recipients.
引用
收藏
页码:139 / 144
页数:6
相关论文
共 34 条
[1]
*AM I ARCH AC ARCH, 1996, GUID DES CONSTR HOSP, P58
[2]
[Anonymous], 1994, Respir Care, V39, P1191
[3]
[Anonymous], 1999, MMWR Recomm Rep, V48, P1
[4]
[Anonymous], 2000, MMWR Recomm Rep, V49, P1
[5]
[Anonymous], 1997, MMWR Recomm Rep, V46, P1
[6]
Cytomegalovirus pp65 antigenemia after autologous marrow and peripheral blood stem cell transplantation [J].
Boeckh, M ;
StevensAyers, T ;
Bowden, RA .
JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (05) :907-912
[7]
Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study [J].
Boeckh, M ;
Gooley, TA ;
Myerson, D ;
Cunningham, T ;
Schoch, G ;
Bowden, RA .
BLOOD, 1996, 88 (10) :4063-4071
[8]
A COMPARISON OF FILTERED LEUKOCYTE-REDUCED AND CYTOMEGALOVIRUS (CMV) SERONEGATIVE BLOOD PRODUCTS FOR THE PREVENTION OF TRANSFUSION-ASSOCIATED CMV INFECTION AFTER MARROW TRANSPLANT [J].
BOWDEN, RA ;
SLICHTER, SJ ;
SAYERS, M ;
WEISDORF, D ;
CAYS, M ;
SCHOCH, G ;
BANAJI, M ;
HAAKE, R ;
WELK, K ;
FISHER, L ;
MCCULLOUGH, J ;
MILLER, W .
BLOOD, 1995, 86 (09) :3598-3603
[9]
CASTAGNOLA E, 1995, BONE MARROW TRANSPL, V15, P977
[10]
*CDCP, 1996, MMWR-MORBID MORTAL W, V45, P737